AI Stock Analysis - Avidity Biosciences (RNA)
Analysis generated September 13, 2025.
Avidity Biosciences is a biopharmaceutical company focused on the discovery, development, and commercialization of novel therapies for the treatment of serious diseases. Their technology platform aims to address challenges in the field of RNA therapeutics, providing a cutting-edge approach to treating diseases at the molecular level.
Stock Alerts - Avidity Biosciences (RNA)
 |
Avidity Biosciences | March 5 Price is down by -6.7% in the last 24h. |
|
Avidity Biosciences | March 2 Price is down by -6.3% in the last 24h. |
|
Avidity Biosciences | February 27 Price is down by -79.4% in the last 24h. |
|
Avidity Biosciences | January 24 Insider Alert: Hughes Steven George is selling shares |
Download our app to get future alerts delivered in real-time.
Alternative Data for Avidity Biosciences
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | N/A | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 10,000 | Sign up | Sign up | Sign up |
| Employee Rating | 90 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | 1 | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 4 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 1,628 | Sign up | Sign up | Sign up |
| X Followers | 852 | Sign up | Sign up | Sign up |
| X Mentions | 26 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 83 | Sign up | Sign up | Sign up |
| Linkedin Employees | 530 | Sign up | Sign up | Sign up |
About Avidity Biosciences
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics.
| Price | $14.67 |
| Target Price | Sign up |
| Volume | 829,241 |
| Market Cap | $229M |
| Dividend Yield | 0% |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
Avidity Biosciences Final Results From Phase 1/2 MARINA Trials Will Be Published In The New England Journal Of Medicine February 19thFebruary 18 - Benzinga |
|
 |
Why Applied Optoelectronics Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving PremarketFebruary 26 - Benzinga |
Novartis delivered high single-digit sales growth, achieved 40% core margin and further advanced the pipeline in 2025February 3 - GlobeNewswire |
|
 |
Harbor Small Cap Growth Fund Q4 2025 Portfolio PerformanceJanuary 29 - SeekingAlpha |
 |
Biotech: Time For A Pause To Start 2026January 1 - SeekingAlpha |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '25 | 12M | 0 | 12M | -174M | -173M | -1.270 |
| Q2 '25 | 3.8M | 138M | -134M | -157M | -170M | -1.210 |
| Q1 '25 | 1.6M | 0 | 1.6M | -116M | -131M | -0.900 |
| Q4 '24 | 3M | 740,000 | 3M | -102M | -120M | -0.800 |
| Q3 '24 | 2.3M | 710,000 | 2.3M | -80M | -97M | -0.650 |
Insider Transactions View All
| McCarthy Teresa filed to sell 113,938 shares at $72.5. January 23 '26 |
| McCarthy Teresa filed to sell 115,391 shares at $72.5. January 23 '26 |
| LEVIN ARTHUR A filed to sell 16,562 shares at $72.5. January 23 '26 |
| MacLean Michael F filed to sell 62,025 shares at $72.5. January 23 '26 |
| MacLean Michael F filed to sell 59,290 shares at $72.5. January 23 '26 |
Similar companies
Read more about Avidity Biosciences (RNA) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, x followers, x mentions, news mentions, customer reviews, business outlook & linkedin employees.
FAQ - Avidity Biosciences
The Market Cap of Avidity Biosciences is $229M.
Currently, the price of one share of Avidity Biosciences stock is $14.67.
The RNA stock price chart above provides a comprehensive visual representation of Avidity Biosciences' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Avidity Biosciences shares. Our platform offers an up-to-date RNA stock price chart, along with technical data analysis and alternative data insights.
As of our latest update, Avidity Biosciences (RNA) does not offer dividends to its shareholders. Investors interested in Avidity Biosciences should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
Some of the similar stocks of Avidity Biosciences are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
